PUBLIC COMPANY
save$PTGXProtagonist Therapeutics, Inc
$PTGX140.06+0.63%Newark, CA, USupdated 1d ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1pre_registration
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PN-881 in Healthy Subjects.
- phase2Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis
- phase2PTG-300 in Subjects With Hereditary Hemochromatosis
- phase3A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera
- phase2Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)
- phase3Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera
- phase2PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 20, 26SELLAli Asif· Chief Financial Officer−$185K↗
routine RSU / option mechanics (1)
- Apr 23, 26giftPATEL DINESH V PH D · President and CEO1,460 sh
🐶 Hiring Signal
next earnings Nov 5, 2026
News
- 6 immunology targets to sustain a mammoth I&I marketJohnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…biospace · 7d ago
- Disc sets up polycythemia vera challenge but Silence maintains leadThe polycythemia vera field is heating up, with Disc Medicine and Silence Therapeutics each advancing next-generation therapies, playing catch-up to Takeda and Protagonist Therapeutics, who won the…biospace · 24d ago
- STAT+: We’re reading about drug pricing deals, a new cancer therapy approval, and moreIn today's Pharmalittle newsletter, drug pricing deals, a new cancer therapy approval, and more of the latest pharma headlines.stat · 1mo ago
- Capricor shares spike on CEO comments; Cytokinetics sues Bristol MyersThe FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the first “Protac” medicine.biopharma_dive · 1mo ago
- Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decisionAs the FDA mulls whether to approve Takeda and Protagonist Therapeutics’ rusfertide, Zealand Pharma has sold its own rights to the blood cancer drug in return for $100 million.fiercebiotech · 1mo ago
Data sources
last refreshed 19m ago
Found something off?
comments(0)
5-min edit window · permanent after that